Breaking news on pharma_industry
Key Pharmacogenomics Resource Expanded By NIH published
Thu, 09 Sep 2010 05:00:00 PDT
To help advance research on how genes affect responses to medicines, the National Institutes of Health is spending $15 million over five years to expand a key resource, the Pharmacogenomics Knowledge Base (PharmGKB). The goal of pharmacogenomics is to use information about a patient's genetic make-up to optimize his or her medical treatment. As the field has grown, so has PharmGKB...
Federal Appeals Court Declines To Reconsider 'Pay-For-Delay' On Generic Drugs published
Thu, 09 Sep 2010 04:00:00 PDT
A federal appeals court on Tuesday said it will not revisit its decision to uphold settlements that allow pharmaceutical companies to pay competitors to keep generic versions of their drugs off the market, The Wall Street Journal reports. "In April, the U.S...
MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment In Open-Label Trial And Completion Of Treatment In QT Trial For LEVADEXtm published
Thu, 09 Sep 2010 03:00:00 PDT
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX...
Enobia Provides Update On Progress With ENB-0040, A Bone-Targeted Enzyme Replacement Therapy For Hypophosphatasia published
Thu, 09 Sep 2010 03:00:00 PDT
Enobia Pharma provided an update on key developments in its comprehensive effort to develop ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy, for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages...
Cylene To Report Recent Advances With First-in-Class CK2 Inhibitor, CX-4945, At International CK2 Conference published
Thu, 09 Sep 2010 03:00:00 PDT
Cylene Pharmaceuticals, Inc. will report recent developments with its first-in-class, oral CK2 inhibitor CX-4945, at the 6th International Conference on Protein Kinase CK2, to be held on September 7-10 in Cologne, Germany, the company announced. CX-4945 is potentially a dynamic anticancer therapeutic, as both a stand-alone drug and for use in combination therapies...
Ariana(R) Pharma Collaborates With The FDA To Facilitate Signature Validation For The Development Of Biomarkers published
Thu, 09 Sep 2010 01:00:00 PDT
Ariana Pharma, a leader in decision support tools and services to accelerate the development and optimal use of drugs and biomarker discovery, announces that it has started a collaboration with the US Food and Drug Administration (FDA)...
UC San Diego To Lead New Pharmacogenomics Project published
Wed, 08 Sep 2010 06:00:00 PDT
An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder...
Cuts To Public Spending On Research Will Jeopardise Funding For Medical Research From Private And Charitable Sources, UK published
Wed, 08 Sep 2010 06:00:00 PDT
The Academy of Medical Sciences has warned that the UK's competitive advantage in medical science is reliant on a Government commitment to maintaining a thriving publicly funded research base. Any cuts risk damaging the UK's rich landscape of medical research funders and would jeopardise the private and charitable funding leveraged by public spending...
Court Denies Sandoz/Momenta's Summary Judgment Of Invalidity In Copaxone(R) Litigation published
Wed, 08 Sep 2010 06:00:00 PDT
Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. District Court for the Southern District of New York has denied a motion for summary judgment filed by Sandoz Inc./Momenta Pharmaceuticals, Inc., that the patents at issue are invalid for indefiniteness. The court has not yet set a trial date...
The Benefits Of Hormone Replacement Therapy Overstated And Harms Downplayed By Ghostwritten Articles published
Wed, 08 Sep 2010 05:00:00 PDT
The first academic analysis of the 1500 documents unsealed in recent litigation against the pharmaceutical giant Wyeth (now part of Pfizer) reveals unprecedented insights into how pharmaceutical companies use ghostwriters to insert marketing messages into articles published in medical journals. Dr...
4th Annual Biomarker Discovery And Development Conference, San Francisco, CA Oct. 20-22, 2010 published
Wed, 08 Sep 2010 03:00:00 PDT
The 4th Annual Biomarker Discovery and Development Conference features presentations of novel technologies to discover biomarkers, how they are utilized to streamline the development process by reducing time and costs and minimize drug attrition associated with safety concerns, and highlight their utility in clinical trials and as companion diagnostics in the clinics...
Children's Hospital Boston And Particle Sciences Cooperate On Translational Medicine Efforts published
Wed, 08 Sep 2010 03:00:00 PDT
Particle Sciences Inc. (PSI), a leading pharmaceutical Contract Research Organization (CRO), has been engaged by Children's Hospital Boston to help advance early stage molecules and drug innovations into new therapeutic products for patient care...
TenX Biopharma Reinitiates Enrollment In Pivotal Phase III, CTCL Trial published
Wed, 08 Sep 2010 03:00:00 PDT
TenX Biopharma, Inc. announced that it has re-initiated enrollment in the pivotal Phase III clinical trial assessing zanolimumab treatment for cutaneous T-cell lymphoma (CTCL) patients. The trial enrollment was suspended in October 2008 while Genmab (CO:GEN) was seeking a out-license agreement to further develop the compound...
To Reach, Perchance To Kill The Cancer: A Soliloquy From Epeius Nanotechnologies Opposes That 'Sea Of Troubles' published
Wed, 08 Sep 2010 03:00:00 PDT
Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, reports the publication of a landmark paper in clinical oncology. Following up on its advanced U.S...
BIO India International Partnering Conference Showcases Vibrant And Growing Indian Biotech Industry To Global Leaders published
Wed, 08 Sep 2010 01:00:00 PDT
The Biotechnology Industry Organization (BIO) will be hosting the first-ever BIO India International Partnering Conference in Hyderabad, India on September 21-22. BIO India will bring together biotechnology and pharmaceutical companies from North America, Europe and Asia to meet and explore business opportunities with India's emerging biotech sector...
INL Selects Vistec's Electron-Beam Lithography System EBPG5200 For Nanotechnology Research published
Tue, 07 Sep 2010 05:00:00 PDT
Vistec Lithography, a leading supplier of advanced electron-beam lithography systems has announced today that the International Iberian Nanotechnology Laboratory (INL) in Braga, Portugal has placed an order for Vistec's electron-beam lithography system EBPG5200...
Hans-Joachim Bohm, Mathai Mammen, Tom Novak And Others To Present At 6th Modern Drug Discovery And Development Summit, Oct 20-22, San Francisco published
Tue, 07 Sep 2010 03:00:00 PDT
The at 6th Modern Drug Discovery and Development Summit will feature plenary keynote presentations from Mathai Mammen, Senior Vice President of Research and Early Clinical Development at Theravance; Gilles J. A. Gallant, Vice-President of Clinical Oncology at Human Genome Sciences; Tom Novak, Ph.D,Senior Vice President of Research & Development, Fate Therapeutics; and Hans-Joachim Bohm, Ph.D...
Stephen Turner And Michael R. Jackson To Present At Assay And Drug Discovery Technologies Conference, San Diego, Sept. 20-21, 2010 published
Tue, 07 Sep 2010 03:00:00 PDT
Stephen Turner, Founder & Chief Technology Officer of Pacific Biosciences and Michael R. Jackson, Vice President, Drug Discovery and Development of Burnham Medical Research Institute will give a keynote presentation at the 5th Assay and Drug Discovery Technologies Conference to be held this year in San Diego, CA Sept. 20-21, 2010 by GTCbio...
Urgent Action Needed To Ensure UK Patients Get Their Medicines, UK published
Tue, 07 Sep 2010 02:00:00 PDT
Urgent action is needed to tackle the worsening problems UK patients are facing when trying to receive their medicine prescriptions...
Key To Slowing Rise Of Antibiotic-Resistant Infections Is Pharmaceutical Conservation published
Tue, 07 Sep 2010 01:00:00 PDT
The United States must focus on conserving the use of antibacterial drugs, or face a public health crisis from rapidly rising rates of antibiotic-resistant infections, according to an analysis just released...
European Medicines Agency Holds First Scientific Workshop On Nanomedicines published
Tue, 07 Sep 2010 00:00:00 PDT
On 2-3 September 2010, the European Medicines Agency (EMA) hosted the first international scientific workshop on nanomedicines. Some 200 European and international participants from 27 countries including Australia, Canada, India, Japan and the United States discussed benefits and challenges arising from the application of nanotechnologies to medicines...
ThromboGenics Presents Positive Pooled Results From The MIVI-TRUST Phase III Program published
Tue, 07 Sep 2010 00:00:00 PDT
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France...
LEVITRA 10mg Orodispersible Tablet For The Treatment Of Erectile Dysfunction Approved In Europe published
Tue, 07 Sep 2010 00:00:00 PDT
The European Commission has approved a new formulation of Levitra® (vardenafil HCI). Levitra 10mg orodispersible tablet will be the first erectile dysfunction (ED) medication available in this novel and convenient formulation...
Novartis And Collaborators Discover Novel Antimalarial Drug Candidate published
Tue, 07 Sep 2010 00:00:00 PDT
Novartis announced that scientists at the Novartis Institute for Tropical Diseases (NITD), in collaboration with researchers from the Genomics Institute of the Novartis Research Foundation (GNF), the Swiss Tropical and Public Health Institute and The Scripps Research Institute have discovered a novel compound that shows promise as a next generation treatment for drug resistant malaria...
Concern About Rosiglitazone (Avandia) And How Drugs Are Regulated And Promoted, BMJ published
Mon, 06 Sep 2010 11:00:00 PDT
There is serious concern about top-selling diabetes drug rosiglitazone (Avandia), its safety, as well as the whole system by which medications are regulated, evaluated and promoted worldwide, according to a BMJ (British Medical Journal) investigation. Dr. Fiona Godlee, BMJ Editor-in-Chief, thinks Avandia should not have been licensed; she believes it should be withdrawn...
)
|
|
